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Abstract
Three synthetic peptides, ILAP, LLAP and MAGVDHI, derived from a Palmaria palmata protein hydrolysate were assessed 
for their antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV in a cell-based in situ 
assay all three peptides significantly increased the half-life of the incretin hormone glucagon-like peptide-1 (GLP-1). ILAP 
and LLAP mediated a significant increase (p < 0.001) in insulin secretion from BRIN-BD11 cells compared to the glucose 
control, while MAGVDHI had no insulinotropic activity at an eqimolar concentration  (10–6 M). A significant increase in the 
concentration of cyclic adenosine monophosphate production in BRIN-BD11 cells mediated by ILAP (p < 0.001) and LLAP 
(p < 0.01) compared to the basal control, would indicate that insulin secretion may be mediated by membrane based activation. 
Furthermore, ILAP and LLAP acted as glucose-dependent insulinotropic polypeptide (GIP) secretagogues, stimulating a 
significant increase (p < 0.01) in the concentration of GIP released from enteroendocrine STC-1 cells compared to the glucose 
control. When tested in vivo in healthy male NIH Swiss mice, ILAP and LLAP, mediated a significant increase (p < 0.01) 
in plasma insulin and decrease (p < 0.05) in blood glucose, respectively, compared to the control. MAGVDHI mediated a 
significant (p < 0.001) sustained reduction in food intake in food deprived trained mice. These results demonstrate that the 
Palmaria palmata peptides studied herein have prospective antidiabetic activity and have the potential to act as agents that 
can be used alone or in combination with drugs, to aid in the prevention and management of Type 2 diabetes mellitus.
Keywords Bioactive peptides · Dipeptidyl peptidase-IV (DPP-IV) inhibition · Glucagon-like peptide-1 (GLP-1) · Glucose-
dependent insulinotropic polypeptide (GIP) · Type 2 diabetes · Palmaria palmata
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ACN  Acetonitrile
AMC  H-Gly-Pro-7-amino-4-methyl 
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cAMP  Cyclic adenosine monophosphate
DMEM  Dulbecco’s modified Eagle’s medium
DPP-IV  Dipeptidyl peptidase-IV
EDTA  Ethylenediaminetetraacetic acid
ELISA  Enzyme-linked immunosorbent assay
FBS  Fetal bovine serum
GIP  Glucose-dependent insulinotropic 
polypeptide
GLP-1  Glucagon-like peptide-1




KRBB  Krebs–Ringer bicarbonate buffer
LDH  Lactate dehydrogenase
LLAP  Leucine–leucine–alanine–proline
MALDI-TOF MS  Matrix assisted laser desorp-
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m/z  Mass to charge ratio
PBS  Phosphate buffered saline
RP-HPLC  Reversed phase-high performance 
liquid chromatography
TFA  Trifluoroacetic acid
T2DM  Type 2 diabetes mellitus
Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic 
condition characterised by a deficiency in the secretion and/
or function of insulin (i.e., insulin resistance), resulting in 
high blood glucose levels (hyperglycaemia; NMIC 2017). 
With the prevalence of T2DM increasing worldwide, in 
particular in countries with increasing obesity incidences, 
effective interventions are required to prevent and man-
age the condition. Initial approaches to the management 
of T2DM includes lifestyle modification, particularly in 
relation to diet and exercise (NMIC 2017). However, these 
modifications are often insufficient to achieve satisfactory 
glycaemic control and pharmacological interventions are 
required. In recent years, a particular focus has been placed 
on the development of gut hormone-based therapies, which 
stimulate the biological activities and/or prolong the action 
of endogenous incretin hormones (Irwin and Flatt 2015). 
These include glucagon-like peptide-1 receptor (GLP-1R) 
agonists (incretin mimetics) and dipeptidyl peptidase (DPP)-
IV inhibitors. Intestinal derived incretin peptides, GLP-1 and 
glucose-dependent insulinotropic polypeptide (GIP), play a 
significant role in postprandial insulin release (Green et al. 
2004). However, GLP-1 and GIP are rapidly degraded by the 
aminopeptidase DPP-IV resulting in the loss of their insuli-
notropic potential in vivo (Deacon 2019). As peptidomimet-
ics, GLP-1R agonists mimic the actions of the endogenous 
hormone GLP-1, where the structural modifications increase 
their stability and bioavailability for activation of the recep-
tor, while DPP-IV inhibitors increase the half-life of circu-
lating incretin hormones (Power et al. 2014; Irwin and Flatt 
2015; Deacon 2019).
Although most synthetic GLP-1 mimetics and DPP-IV 
inhibitory agents are well tolerated, adverse side-effects, 
such as mild infections (common cold, urinary and upper 
respiratory tract infections), headaches, mild to moderate 
nausea, vomiting and diarrhoea have been reported (Krush-
ner and Gorrell 2010; Lund et al. 2014). While safety con-
cerns linking GLP-1 therapy with pancreatitis, pancreatic 
and thyroid cancer and glucagon-producing neuroendocrine 
tumours have been alleviated, pharmacovigilance around the 
use of GLP-1 drugs is still required, particularly in relation 
to patients with increased risk or a history of pancreatitis 
or thyroid cancer (Irwin and Flatt 2015). Furthermore, to 
date, the development of incretin mimetics has been directed 
predominantly towards single molecules that modulate indi-
vidual peptide receptor targets. However, future research 
aims to identify multi‐agonist components which simultane-
ously modulate multiple receptor signalling pathways. This 
may be the identification of single components with mul-
tifunctional activities or the generation of designer hybrid 
peptides that can modulate multiple regulatory peptide hor-
mone receptor pathways (Irwin and Flatt 2015; Brandt et al. 
2018).
Due to the adverse side-effects posed by existing synthetic 
T2DM drugs the identification of natural agents that can be 
used alone or in combination with T2DM drugs, to aid in 
the prevention and management of T2DM has gained sig-
nificant interest in recent years. Evidence-based research has 
shown that dietary proteins, protein hydrolysates, peptides 
and amino acids can beneficially regulate glycaemic control 
with the extent of the response varying vastly depending on 
the primary sequence of the peptides and amino acids gener-
ated during digestion (Newsholme et al. 2006; Promintzer 
and Krebs 2006; Oseguera-Toledonet al. 2014).
Numerous food protein-derived peptides have been shown 
to exhibit DPP-IV inhibitory activity (Nongonierma and 
FitzGerald 2017). While food protein derived peptides may 
not be as potent as synthetic drugs they have the potential to 
be used in combination with such therapies thereby reducing 
drug dosage, or can be employed as part of dietary strate-
gies to prevent or control the disorder. In a previous study 
three novel peptides (Ile–Leu–Ala–Pro, Leu–Leu–Ala–Pro 
and Met–Ala–Gly–Val–Asp–His–Ile), with promising DPP-
IV inhibitory activity  (IC50 values in the range 43–159 μM) 
were identified within a protein hydrolysate generated from 
the red macroalgal species Palmaria palmata (Harnedy 
et al. 2015). All three peptides were shown to be resistant 
to degradation following simulated gastrointestinal diges-
tion, which would suggest that these peptides may survive 
gastrointestinal transit and exert effects in vivo (Harnedy 
et al. 2015). The objective of the study herein was firstly to 
investigate the effect of these peptides on in situ DPP-IV 
inhibitory activity and in vitro insulinotropic, GLP-1 and 
GIP stimulatory and GLP-1 protective activity and secondly 
to investigate the effect of oral consumption of these pep-




T h e  s y n t h e t i c  p e p t i d e s 
Ile–Leu–Ala–Pro (ILAP), Leu–Leu–Ala–Pro (LLAP) 
and Met–Ala–Gly–Val–Asp–His–Ile (MAGVDHI) were 
obtained from Thermo Fisher Scientific (Ulm, Germany). 
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H-Gly-Pro-7-amino-4-methyl coumarin (AMC) and Dipro-
tin-A (IPI: Ile-Pro-Ile) were obtained from Bachem Feinche-
mikalien (Bubendorf, Switzerland). GLP-1 (total) and GIP 
(total) ELISA assay kits were provided by Millipore (Hert-
fordshire, UK), lactate dehydrogenase (LDH) kit by Pro-
mega (Madison, WI, USA) and cAMP Parameter detection 
kit by R&D Systems (Abingdon, UK). Fetal bovine serum 
(FBS), Hank’s buffered saline solution (HBSS 10 ×), penicil-
lin–streptomycin (0.1 g/L), RPMI-1640 culture media, Dul-
becco’s modified Eagle’s medium (DMEM) containing high 
glucose and trypsin/EDTA (10 ×) were obtained from Gibco 
Life Technologies Ltd. (Paisley, Strathclyde, UK). Radio-
labelled sodium iodide (Na 125I, IMS 100 mCi/mL) was 
purchased from Perkin Elmer (Buckinghamshire, UK). Rat 
insulin standard was purchased from Novo Industria (Copen-
hagen, Denmark). All other reagents including human Cau-
casian colon adenocarcinoma (Caco-2) cells were supplied 
by Sigma Chemical Company Ltd. (Wicklow, Ireland).
Cytotoxicity Assay
The cytotoxicity of the peptides  (10–6 M) on cell culture 
lines was determined by the release of LDH in cell super-
natants obtained from acute insulin, GLP-1 and GIP release 
experiments. LDH activity in the cell supernatants was 
determined using a CytoTox 96® non-radioactive cytotox-
icity assay kit, where 50 μL of cell supernatant was mixed 
with 50 μL of LDH substrate solution. Following 30-min 
incubation in the dark at room temperature, 50 μL of stop 
solution was added and the absorbance was determined at 
595 nm.
In Situ Quantification of DPP‑IV Inhibitory Activity 
in Caco‑2 Cells
The inhibition of DPP-IV in Caco-2 cells (passage 44–46) 
was determined according to the method described by 
Caron et al. (2017) with some modifications (Harnedy-
Rothwell et al. 2020). The cells were grown in minimum 
essential Eagle’s medium supplemented with 10% FBS, 
100 U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/
mL amphotericin B and 2 mM glutamine at 5%  CO2 and 
37 °C for 5 days. The cells were then trypsinised and seeded 
at a density of 20,000 cells/well in a 96-well optical black 
plate (Costar, Corning, NY, USA). The culture media was 
removed after 16 h contact and cells were washed with 100 
μL phosphate buffered saline (PBS, 0.01 M, pH 7.4). Fresh 
PBS (125 μL) was added to the well followed by 25 μL of 
each test peptide solution (0.025 to 2.500 mM prepared in 
PBS) or PBS (no inhibition control). The DPP-IV inhibition 
reaction was initiated by the addition of 50 μL of substrate 
(Gly-Pro-AMC) and the fluorescence was recorded every 
2 min for 1 h using a plate reader (Biotek Synergy, HT, 
USA) at 37 °C. Excitation and emission wavelengths were 
at 360 and 460 nm, respectively. DPP-IV inhibition was 
defined as the percentage of DPP-IV activity inhibited by 
a given concentration of peptide compared to the control. 
Activity was expressed as mean  IC50 value (inhibitory con-
centration, which inhibited DPP-IV activity by 50%) ± SD 
obtained from three independent replicates (n = 3).
In Vitro Assessment of GLP‑1 Protective Effects
The inhibition of GLP-1(7–36) amide hydrolysis by the 
peptides when incubated in the presence of DPP-IV was 
assessed using reversed phase-high performance liquid chro-
matography (RP-HPLC). In brief, 30 μL of GLP-1(7–36) 
amide  (10–6 M) was combined with either 30 μL of peptide 
 (10–6 M), Diprotin A  (10–6 M) or distilled water (blank) and 
430 μL triethanolamine buffer (pH 7.4). Human DPP-IV 
(10 μL, 5 mU) was added and incubated at 37 °C for 0, 2, 4, 
8 and 24 h. The reaction was terminated by the addition of 
50 μL of 10% (w/v) trifluoroacetic acid (TFA).
Samples were analysed using a RP-HPLC (Thermo 
Finnigan Surveyor) equipped with a UV/VIS detector 4 
port gradient inlet solvent proportioning pump, a Rheo-
dyne 7125i injector with a 1 mL loop and multi-sampler 
(Thermo Finnigan) equipped with a 250 μL reservoir and 
100 μL column loop. Samples were separated using a Aeris 
Peptide C18 RP column (250 × 46 mm, 3.6 μm; Phenom-
enex (Macclesfield, Cheshire, UK) with mobile phase A 
and B consisting of 0.12% (v/v) TFA in HPLC grade  H2O 
and 0.10% (v/v) TFA in 70% (v/v) HPLC grade acetoni-
trile/water, respectively. The following gradient was used: 
0–10 min: 0–30% B; 11–50 min: 30–70% B; 51–55 min: 
70–100% B; 56–65 min; 100% B; 66 min; 0% B. The flow 
rate was set at 1 mL/min and the absorbance of the eluent 
was monitored at 214 nm. The eluted peaks (containing 
active and inactive GLP-1) were collected and analysed 
using matrix assisted laser desorption ionisation time of 
flight mass spectrometry (MALDI-TOF MS; PerSeptive 
Biosystems Voyager-DE Biospectrometer, Hertfordshire, 
UK). A 10 mg/mL solution of α-cyano-4-hydroxycinnamic 
acid (CHCA) was prepared in 80% (v/v) ethanol contain-
ing 0.1% (v/v) TFA, mixed thoroughly and centrifuged for 
2 min at 2000×g. A 10 μL aliquot of the CHCA superna-
tant was mixed with 1.5 μL of the collected HPLC peak 
and pipetted onto a predefined well in a 100-well stainless 
steel plate and allowed to dry. The plate was then inserted 
into the MALDI-TOF MS. Internal mass calibration of 
the instrument was preformed prior to sample analysis 
using Peptide Calibration Mix 2 (LaserBio Labs, Spohia-
Antipolis, Cedex, France) which contained 4 individual 
peptides (Neurotensin, ACTH fragment 18–39, insulin 
bovine β-chain oxidised and bovine insulin with monoi-
sotopic masses of 1672.9176, 2465.1989, 3494.6514 and 
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5730.6087 Da, respectively). All sample measurements 
were collected in linear positive ionisation mode using 
50 laser shots/spectrum. The accelerating voltage was 
maintained at 20,000 V, the grid voltage and guide wire 
voltages were set at 93% and 0.05%, respectively, of the 
accelerating voltage. The nitrogen laser, set at 337 nm, was 
directed towards the densest area of the sample/matrix spot 
and the laser intensity adjusted to obtain the best spectral 
response. The mass/charge ratio (m/z) was plotted against 
relative abundance.
In Vitro Insulin Secretion
The effect of the peptides on in vitro insulin secretion was 
examined using rat pancreatic beta BRIN-BD11 cells, 
whose characteristics have been reported previously 
(McClenaghan et al. 1996). BRIN-BD11 cells were seeded 
into 24-well plates (1.5 ×  105 cell/well) and allowed to 
attach overnight on incubation at 37 °C. Following 40 min 
of pre-incubation with 1.1 mmol/L glucose; 37 °C, the 
cells were incubated (20 min; 37 °C) in the presence of 
5.6 mmol/L glucose with a range of test peptide concentra-
tions  (10–6–10–12 M). After 20 min of incubation, 900 μL 
buffer was removed from each well and stored at − 20 °C 
before the determination of insulin by radioimmunoassay 
(Flatt and Bailey 1981).
Acute Intracellular cAMP Production
Acute intracellular cAMP production was assessed with 
BRIN-BD11 cells. Cells were prepared as above and follow-
ing overnight attachment the cells were washed with HBSS 
buffer before incubation (20 min, 37 °C) with the peptides 
 (10–6 M) in the presence of 200 μM 3-isobutyl-1-methyl-
xanthine. The medium was then removed, the cells were 
lysed and the concentration of cAMP in the cell lysates was 
determined using a cAMP detection kit (R&D Systems, 
Abingdon, UK) according to the manufacturer’s instructions.
In Vitro GLP‑1 Secretion
In vitro effects of the peptides on GLP-1 secretion from 
murine enterendocrine GLUTag cells were determined as 
described previously (Ojo et al. 2013). In brief, cells were 
seeded into 24 well plates (1.5 ×  105 cell/well) and incubated 
overnight at 37 °C. After a pre-incubation step (40 min, 
37 °C), the cells were presented with the peptides  (10–6 M) 
prepared in 2 mM glucose and incubated for 2 h at 37 °C. 
The supernatant was then removed and stored at − 20 °C 
prior to measurement of GLP-1 concentration using a Total 
GLP-1 sandwich ELISA assay kit (Millipore, Hertsfordshire, 
UK) according to the manufacturer’s instructions.
In Vitro GIP Secretion
In vitro effects of the peptides on GIP secretion were meas-
ured using the murine enteroendocrine STC-1 cells. STC-1 
cells were cultured in DMEM media containing 4.5 g/L 
d-glucose, 17.5% FBS, 100 U/mL penicillin, 100 mg/L 
streptomycin and incubated in a 5% humidified air atmos-
phere at 37 °C. Cells were passaged at 80–90% conflu-
ence. Cells were then gently washed in 10 mL of HBSS 
prior to incubating with 3 mL of pre-warmed 1% trypsin/
EDTA at 37 °C for 5–8 min. Detached cells were observed 
using a phase contrast microscope (Zeiss, Germany). Clus-
ters of cells were gently broken by aspiration for single cell 
counting. Cells were centrifuged at 900 rpm for 5 min. Cell 
supernatant was then removed and cells were re-suspended 
in a known volume of pre-warmed DMEM media. A sin-
gle aliquot of 100 μL of re-suspended cells was mixed with 
100 μL of Trypan blue and was then transferred for count-
ing to a Neubauer haemocytometer (Scientific Supplies 
Co., Middlesex, UK). Cells were seeded at a cell density 
of 1.5 ×  105 cell/well in 1 mL of DMEM containing 4.5 g/L 
d-glucose and left for 48 h to adhere. Media was removed 
and replaced with 1 mL of priming KRBB (11 mM NaCl, 
4.7 mM KCl, 1.28 mM  CaCl2.2H2O, 1.2 mM  KH2PO4, 
1.2 mM  MgSO4.7H2O, 10 mM  NaHCO3, 25 mM HEPES, 
0.1% (w/v) bovine serum albumin, pH 7.4) supplemented 
with 1.1 mM glucose and incubated at 37 °C for 40 min. 
The KRBB was removed and replaced with KRBB contain-
ing 2 mM glucose and peptides  (10–6 mol/L) and incubated 
for 2 h, after which 900 μL of the supernatant was removed 
from each well and was stored at -20 °C until analysed via 
ELISA. Analysis of total GIP was performed using a sand-
wich ELISA (Rat/Mouse, Millipore, Herfordshire, UK) kit 
according to the manufacturer’s instructions.
Acute Glucose Lowering Effect of Peptides 
via Intraperitoneal Injection
Acute animal studies were carried out using male NIH Swiss 
mice (10 to 12 weeks old; Harlan Ltd., Blackthorne, UK) 
fed a standard rodent maintenance diet that contained 10% 
fat, 30% protein, and 60% carbohydrate with a total energy 
of 12.99 kJ/g; (Teklad Natural diet for rodents) (Envigo, 
Blackthorn, UK). Mice were housed in an air-conditioned 
room maintained within a temperature range of 22 ± 2 °C 
with a 12 h light: 12 h dark cycle and had free access to 
drinking water and food. All animal experiments were con-
ducted according to U.K. Home Office Regulations [U.K. 
Animals (Scientific Procedures) Act 1986] and EU Directive 
2010/63EU for animal experiments, and were approved by 
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the Ulster University Animal Welfare and Ethical Review 
Board. All necessary steps were taken to prevent any poten-
tial animal suffering.
Plasma glucose and insulin responses were evalu-
ated after intraperitoneal (i.p.) injection of glucose alone 
(18 mmol/kg body weight [BW]) or in combination with test 
peptides (25 nmol/kg BW) in 8 h fasted normal NIH mice. 
Food was withheld during experimentation, however, access 
to water was available. Prior to compound administration, a 
fasting blood sample was analysed for glucose concentration 
using a handheld glucometer (Bayer Contour, Leverkusen, 
Germany). Blood samples were collected at 0, 15, 30, 60, 90 
and 120 min post administration from the tail vein of con-
scious mice and added into chilled fluoride/heparin micro-
centrifuge tubes (Sarstedt, Numbrecht, Germany). The blood 
samples were centrifuged at 18,360×g for 3 min (Universal 
320, Hettich Zentrifugen, Germany). Blood glucose concen-
trations were measured using an Ascencia Contour blood 
glucose meter (Bayer Healthcare, Newbury, UK). Plasma 
insulin was determined using a modified dextran-coated 
charcoal RIA (Flatt and Bailey 1981).
Investigating Reduction of Food Intake in 3 h 
Trained Feeding HsdOla:TO Mice
HsD:Ola:T0 mice (8 weeks old) were obtained from Envigo, 
Blackthorn, UK. Mice were housed in an air-conditioned 
room maintained within a temperature range of 22 ± 2 °C 
with a 12 h light:12 h dark cycle. Drinking water and stand-
ard rodent diet was freely available. Mice were trained to 
eat for 3 h per day, by reducing food intake gradually from 
24 to 10 h to 6 h and 3 h per day, over a period of 3 weeks 
(O’Harte et al. 2018). Groups of 21 h fasted mice (n = 8) 
were administered peptides (50 nmol/kg bw) within a saline 
vehicle (0.90% (w/v) NaCl) via intraperitoneal injection. 
Mice were only allowed access to food post-injection (at 
10.00 am) and the food was weighed at 30 min intervals up 
until 180 min and food was then removed until the following 
day. Food intake was calculated and compared to the saline 
only (0.90% (w/v) NaCl) control group.
Statistical Analysis
Statistical analyses were performed using the statistical 
software program SPSS (Version 22, IBM Inc., Chicago, 
IL, USA) and GraphPad Prism version 5.0 (GraphPad Soft-
ware Inc., San Diego, CA, USA). Data was expressed as 
mean ± SEM with values compared using one-way analysis 
of variance (ANOVA) followed by student’s t test, Tukey’s 
and Games–Howell post-hoc tests where applicable. Incre-
mental area under the curve (AUC) for plasma glucose and 
insulin were calculated using GraphPad Prism.
Results and Discussion
Effect of Palmaria palmata‑Derived Peptides 
on Insulin Release from BRIN‑BD11 Cells In Vitro
The Palmaria palmata-derived peptides, ILAP and LLAP, 
were shown to stimulate the secretion of insulin from cul-
tured pancreatic BRIN-BD11 cells in a dose-dependent 
manner from  10–12 to  10–6 M (Fig. 1a). While both pep-
tides  (10–6 M) were shown to mediate a significant increase 
(p < 0.001, 2.0-fold) in insulin secretion from BRIN-BD11 
cells compared to the 5.6 mM glucose control, the peptide 
Fig. 1  Effects of Palmaria palmata peptides ILAP, LLAP and MAG-
VDHI at a concentration of   10–6–10–12 M on insulin secretion from 
and b  10–6 M on cyclic adenosine monophosphate (cAMP) produc-
tion in BRIN-BD11 cells. Values are expressed as mean ± SEM. 
(n = 8). **p < 0.01 and ***p < 0.001 compared to buffer/media con-
taining 5.6 mM glucose (black bar, control). Treatment bars represent 
cells cultured with 5.6 mM glucose and peptides
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MAGVDHI had no insulinotropic activity at an eqimolar 
concentration (Fig. 1a).
All three peptides had no cytotoxic effects at  10–6 M 
(LDH assay, Supplementary Fig. S1). Significantly higher 
stimulatory activity was observed with 10  pM ILAP 
(p < 0.01) compared to 1 nM LLAP (p < 0.01), which would 
indicate that ILAP is more potent than LLAP. Further stud-
ies are required to assess the impact of presenting combina-
tion of peptides to the pancreatic cells in order to determine 
if synergistic effects on insulin secretion may take place.
To date, only peptides derived from casein and boarfish 
(Capros aper) proteins have been shown to stimulate the 
secretion of insulin from cultured pancreatic BRIN-BD11 
cells (Drummond et al. 2018; Harnedy-Rothwell et al. 2020). 
Information in relation to the structure–activity relationship 
of food-derived insulinotropic peptides is non-existent, how-
ever, a similar trend to that seen with ILAP and LLAP herein 
was seen with the boarfish-derived peptides IPVDM and 
LPVDM, where peptides with isoleucine at position 1 had 
higher insulinotropic activity than the same peptides with 
Leu at position 1 (Harnedy-Rothwell et al. 2020). While the 
insulin secretory activity observed with ILAP and LLAP 
was lower than that mediated by Exendin-4, a GLP-1 paral-
ogue, which was approved for treatment of T2DM in 2005, 
the activity exhibited by both peptides was similar to that 
observed with other promising peptides under investigation 
such as xenin, its enzymatically stable C-terminal octa-
peptide fragments, xenin 18–25 and xenin 18–25 Gln and 
stable hybrid peptide  (DAla2) GIP/xenin-8-Gln (Irwin et al 
2015; Martin et al 2016; Hasib et al. 2017). The signifi-
cant increase in the concentration of cAMP released from 
BRIN-BD11 cells (Fig. 1b) when incubated in the presence 
of ILAP (p < 0.001) and LLAP (p < 0.01) compared to the 
basal control would suggest a downstream cascade effect 
which is likely to be due to membrane based activation, how-
ever, further work is needed to elucidate its mechanism of 
action on insulin secretion. In contrast, the concentration 
of cAMP detected on incubation of BRIN-BD11 cells with 
MAGVDHI was similar to that seen with the basal glu-
cose control (Fig. 1b). This is in agreement with the results 
obtained previously showing the inability of MAGVDHI to 
stimulate the secretion of insulin from BRIN-BD11 cells 
beyond control values.
Effect of Palmaria palmata‑Derived Peptides 
on Release of the Incretin Hormones GLP‑1 and GIP 
In Vitro
A defect in the postprandial insulin-secretory incretin 
response, mediated by the gut hormones GLP-1 and GIP, 
is a specific pathophysiological characteristic of T2DM. 
The main impairments of this include reduced postprandial 
GLP-1 secretion and less effective GIP incretin action during 
prolonged hyperglycaemia in diabetes (Holst et al. 2011). All 
three Palmaria palmata-derived peptides failed to stimu-
late the secretion of GLP-1 from murine enteroendocrine 
cells when assessed at 1 μM (data not shown). However, the 
peptides which in a previous study were shown to mediate 
potent DPP-IV inhibitory activity in the conventional in vitro 
assay  (IC50 values in the range 43–159 μM), displayed good 
DPP-IV inhibitory activity in a cell-based in situ assay  (IC50 
values in the range 126–358 μM, Harnedy et al. 2015). Fur-
thermore, all three peptides mediated a protective effect for 
GLP-1 by inhibiting its degradation by DPP-IV (Fig. 2). The 
in vitro half-life of GLP-1 was increased from 1.75 h when 
incubated with DPP-IV alone to 8, 10.8 and 13 h, when co-
incubated with LLAP, ILAP and MAGVDHI, respectively 
(Fig. 2).
In contrast to the results observed with GLP-1, ILAP and 
LLAP acted as GIP secretagogues, stimulating a significant 
increase in the concentration of GIP released from murine 
enteroendocrine STC-1 cells compared to the 2.0 mM glu-
cose control (p < 0.01, Fig. 3). All three peptides had no 
cytotoxic effects in STC-1 cells at  10–6 M (data not shown). 
Fig. 2  Protective effect of Pal-
maria palmata derived peptides 
 (10–6 M) against dipeptidyl 
peptidase-IV (DPP-IV) degra-
dation of active glucagon-like 
peptide (GLP)-1(7–36 amide). 
Values are mean ± SEM (n = 3). 
**p < 0.01 and ***p < 0.001 
compared to GLP-1 + DPP-IV 
alone. Diprotin A (IPI) was used 
as a positive control at  (10–6 M). 
Arrows indicate the half-life (h)
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To the best of our knowledge, this appears to be the first 
report of food protein-derived peptides stimulating the secre-
tion of GIP from STC-1 cells. However, MAGVDHI failed 
to stimulate such a response. Although originally believed 
to be involved in inhibiting gastric acid secretion, the pri-
mary physiological role of GIP is now considered to be as 
a postprandial insulin secretagogue (Irwin and Flatt 2015). 
GIP exerts its insulin secretory action through agonistic 
effects on a specific G protein-coupled receptor family GIP 
receptor on the surface of pancreatic β-cells. This increases 
intracellular cAMP generation and subsequent influx of  Ca2+ 
ions leading to exocytosis of insulin granules (Moffett et al. 
2015). Furthermore, GIP is believed to act as a β-cell growth 
factor and to promote β-cell survival (Kubota et al. 1997; 
Ehses et al. 2003). Due to its promising biological activity at 
β-cell level there has been significant interest in the potential 
for GIP-based pharmaceuticals as antidiabetic agents, how-
ever, as with GLP-1 therapies, the pharmacokinetic profile of 
GIP is hindered due to the rapid degradation of this peptide 
in vivo by DPP-IV. More recently, the dual agoinst GLP-1/
GIP peptide appears to have a promising therapeutic profile 
(Frias et al. 2018) and is currently in stage 3 clinical trials. 
DPP-IV inhibitors are known to increase the circulating half-
lives of both of these incretin hormones which also enhances 
their antidiabetic action.
The results of in vitro studies herein show that ILAP 
and LLAP stimulate the secretion of insulin and GIP from 
cultured pancreatic β-cells and murine STC-1 cells, respec-
tively. This suggests that the peptides have multifunctional 
activities and may have the potential to stimulate the release 
of insulin from β-cells by multiple mechanisms. While both 
peptides failed to directly stimulate the secretion of GLP-1 
from GLUTag cells, they do, however, protect the incre-
tin hormone GLP-1 through inhibition of DPP-IV. In addi-
tion, GIP is thought be the most potent of the two incretin 
hormones (associated with 25–70% of the post meal insulin 
response) (Gasbjerg et al. 2020). In addition, GIP is thought 
to generate neuronal signals to more distal GLP-1 producing 
L-cells and promote its postprandial elevation where it too 
acts as a potent insulinotropic agent (Martin et al. 2020). 
In contrast, MAGVDHI only mediated DPP-IV inhibitory 
activity.
Acute Glucose‑Lowering and Insulinotropic Actions 
of Palmaria palmata‑Derived Peptide in Lean Mice
The acute in vivo effects of Palmaria palmata-derived ILAP, 
LLAP and MAGVDHI on glucose homeostasis were stud-
ied in normal healthy NIH Swiss mice (Fig. 4). Over the 
time course of the study (0–120 min) a significant (p < 0.05) 
reduction in plasma glucose concentration was observed 
with LLAP at 60 min only post injection compared to the 
glucose control. The plasma glucose area under the curve 
(AUC) for LLAP, however, was significantly lower than that 
observed with the control mice (p < 0.05, Fig. 4). In con-
trast, ILAP and MAGVDHI failed to stimulate a significant 
decrease in plasma glucose concentration at any of the time 
points post injection compared to mice receiving glucose 
alone (Fig. 4). While both ILAP and LLAP increased plasma 
insulin in mice receiving the peptides when compared with 
those that received glucose alone, a significant increase was 
observed only with ILAP (AUC 0–120 min, p < 0.01, Fig. 4). 
The plasma insulin AUC 0–120 min for MAGVDHI was similar 
to that observed in the mice who receiving glucose alone 
indicating that it did not possess a glycaemic controlling 
potential.
At present there are no clear explanation for the effects 
observed with ILAP and LLAP. It may, for example, be that 
LLAP can somehow improve tissue insulin sensitivity, caus-
ing a glucose lowering effect without an apparent or obvious 
rise in circulating insulin. It is possible that ILAP mediates 
competing actions on insulin and glucagon and this might 
explain the significant rise in insulin which does not ulti-
mately cause a reduction in circulating glucose. However, 
further detailed studies are required to elucidate the different 
responses observed herein.
It is unclear if the mechanism by which circulating 
insulin was elevated in mice injected with ILAP is either 
via DPP-IV inhibition and improvement in GLP-1 or GIP 
action upon the pancreas, stimulation of GIP, or direct 
pancreatic interaction and promotion of insulin secre-
tion. Expanding on the knowledge that the peptide is 
capable of inhibiting DPP-IV, as displayed herein and 
previous studies, co-injection of the ILAP with GLP-1 
further improved the glucose lowering effect versus the 
GLP-1 only injected group, when challenged via the same 
glucose concentration; however, improvement beyond 
GLP-1 only was marginal when analysed via AUC (data 
Fig. 3  Effect of Palmaria palmata peptides a ILAP, b LLAP and c 
MAGVDHI  (10–6  M) on glucose-dependent insulinotropic poly-
peptide (GIP) release from STC-1 cells. Values are expressed as 
mean ± SEM (n = 3). **p < 0.01 compared to 2.0 mM glucose control. 
ΔΔp < 0.01 compared to other peptides
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not shown). Thus, further work is required to determine 
the mechanism by which circulating insulin concentration 
was elevated in mice injected with ILAP.
The Palmaria palmata-derived peptides were also 
assessed for their ability to reduce food intake in the food 
restricted trained mice. Groups of trained mice which 
had access to food for 3 h per day were used to assess 
the effect upon food intake during food availability at 
30 min intervals. LLAP had no effect upon food intake, 
whereas ILAP mediated a significant reduction in food 
intake but only at 180 min compared to the saline control 
(Fig. 5, p < 0.05). Interestingly, MAGVDHI resulted in a 
significant sustained reduction in food intake from 90 to 
180 min with an overall food reduction across the entire 
group of mice averaging 45% versus the control group 
(Fig. 5). The in vitro studies herein show that MAGVDHI 
has no insulinotropic activity when incubated with BRIN-
BD11 cells. This would indicate that the mechanism by 
which this peptide mediates the satiety effects observed 
in vivo is insulin independent and potentially via other 
satiety hormone secretion mechanisms. However, further 
studies are required to confirm this observation.
Conclusion
This study shows that the food protein-derived peptides, 
ILAP and LLAP, stimulated the secretion of insulin and 
GIP from cultured pancreatic β-cells and enteroendocrine 
cells, respectively. Additionally, they exhibited DPP-IV 
inhibitory activity in situ and significantly increased the 
half-life of the incretin hormone GLP-1. While beneficial 
effects on different diabetic markers were observed in vivo 
with the two peptides in healthy lean mice following intra-
peritoneal injection further studies are required to assess 
the efficacy of the peptides following oral administration if 
they are to be employed as part of dietary strategies to pre-
vent or control T2DM. Furthermore, in order to investigate 
the anti-diabetic potential of the Palmaria palmata derived 
peptides in vivo assessment in diabetic animal models is 
required in the first instance with subsequent studies in 
humans which are early stage/pre-diabetic or have been 
diagnosed with T2DM. In addition, MAGVDHI mediated 
a reduction in food intake in trained mice, however, fur-
ther work is required to assess the effect of this peptide 
on appetite, energy intake and metabolic control during 
Fig. 4  Acute effect of Palmaria palmata peptides (ILAP, LLAP and 
MAGVDHI) on glucose tolerance in normal mice. Blood glucose (a) 
and plasma insulin (b) concentrations were measured before and after 
intraperitoneal injection of the peptide (25  nmol/kg body weight) 
together with glucose (18  mmol/kg/body weight). Blood glucose 
and plasma insulin area under the curve (AUC) values for 0–120 min 
post-injection are also shown. Values are expressed as mean ± SEM 
(n = 8). *p < 0.05 and **p < 0.01 compared to glucose alone
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chronic mouse studies and to determine the mechanism by 
which it mediates its satiety effect. Multiple-acting co-ago-
nist peptides represent novel therapeutic agents which may 
be beneficial in providing a mitigation strategy against the 
growing global health challenges of T2DM, obesity and 
related metabolic diseases (Irwin et al. 2015; Frias et al. 
2018). While these natural peptides may not be as potent 
as existing synthetic mimetics they could be used in com-
bination with synthetic drugs thus allowing for a reduction 
in conventional drug dosage, which in turn could lead to 
reduced side-effects and healthcare costs.
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